Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + cyclophosphamide + capecitabine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of docetaxel, cyclophosphamide, and capecitabine. This regimen is primarily used in the adjuvant treatment of triple-negative breast cancer (TNBC). Clinical trials have shown that adding capecitabine to standard docetaxel and cyclophosphamide treatment significantly improves disease-free survival in patients with early TNBC after definitive surgery.
- Other names
- TX+CEX
02
Targets
MicrotubuleDNATYMP (Thymidine phosphorylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + cyclophosphamide + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + cyclophosphamide + capecitabine.